Veru (NASDAQ:VERU) Receives New Coverage from Analysts at Raymond James

Raymond James initiated coverage on shares of Veru (NASDAQ:VERUFree Report) in a research report sent to investors on Thursday morning, MarketBeat reports. The brokerage issued an outperform rating and a $3.00 target price on the stock.

Separately, HC Wainwright reissued a buy rating and set a $2.00 price target on shares of Veru in a research report on Thursday, February 8th.

Get Our Latest Analysis on Veru

Veru Trading Up 8.3 %

Shares of VERU opened at $0.70 on Thursday. The firm’s 50-day moving average price is $0.53 and its 200-day moving average price is $0.73. The firm has a market capitalization of $96.35 million, a price-to-earnings ratio of -0.62 and a beta of -0.23. Veru has a 1-year low of $0.36 and a 1-year high of $1.52.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. UBS Group AG raised its holdings in Veru by 2.3% in the second quarter. UBS Group AG now owns 39,216 shares of the company’s stock worth $443,000 after buying an additional 890 shares during the last quarter. Legal & General Group Plc raised its holdings in Veru by 5.5% in the second quarter. Legal & General Group Plc now owns 22,570 shares of the company’s stock worth $255,000 after buying an additional 1,179 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Veru by 2.5% during the third quarter. Alliancebernstein L.P. now owns 66,500 shares of the company’s stock valued at $766,000 after purchasing an additional 1,600 shares during the last quarter. Creative Planning raised its holdings in shares of Veru by 11.5% during the second quarter. Creative Planning now owns 20,702 shares of the company’s stock valued at $234,000 after purchasing an additional 2,138 shares during the last quarter. Finally, XTX Topco Ltd raised its holdings in shares of Veru by 18.7% during the first quarter. XTX Topco Ltd now owns 14,426 shares of the company’s stock valued at $70,000 after purchasing an additional 2,270 shares during the last quarter. 47.16% of the stock is owned by hedge funds and other institutional investors.

About Veru

(Get Free Report)

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

Featured Articles

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.